- Home
- ATXS vs PHAT Comparison
ATXS vs PHAT Comparison
Compare ATXS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- PHAT
- Stock Information
- Founded
- ATXS 2008
- PHAT 2018
- Country
- ATXS United States
- PHAT United States
- Employees
- ATXS N/A
- PHAT N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- PHAT Health Care
- Exchange
- ATXS Nasdaq
- PHAT Nasdaq
- Market Cap
- ATXS 401.2M
- PHAT 465.0M
- IPO Year
- ATXS 2015
- PHAT 2019
- Fundamental
- Price
- ATXS $6.81
- PHAT $5.67
- Analyst Decision
- ATXS Strong Buy
- PHAT Strong Buy
- Analyst Count
- ATXS 6
- PHAT 4
- Target Price
- ATXS $25.67
- PHAT $23.00
- AVG Volume (30 Days)
- ATXS 244.9K
- PHAT 1.0M
- Earning Date
- ATXS 03-03-2025
- PHAT 03-06-2025
- Dividend Yield
- ATXS N/A
- PHAT N/A
- EPS Growth
- ATXS N/A
- PHAT N/A
- EPS
- ATXS N/A
- PHAT N/A
- Revenue
- ATXS N/A
- PHAT $26,270,000.00
- Revenue This Year
- ATXS N/A
- PHAT $7,453.23
- Revenue Next Year
- ATXS N/A
- PHAT $226.38
- P/E Ratio
- ATXS N/A
- PHAT N/A
- Revenue Growth
- ATXS N/A
- PHAT N/A
- 52 Week Low
- ATXS $6.64
- PHAT $5.21
- 52 Week High
- ATXS $16.90
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- ATXS 31.94
- PHAT 39.59
- Support Level
- ATXS $6.77
- PHAT $5.50
- Resistance Level
- ATXS $7.30
- PHAT $6.21
- Average True Range (ATR)
- ATXS 0.30
- PHAT 0.40
- MACD
- ATXS 0.02
- PHAT 0.07
- Stochastic Oscillator
- ATXS 14.66
- PHAT 38.69
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.